Dashboard
Manage Tickers

GILD GILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 118.95 $ -5.07 (-4.09 %)    

Friday, 07-Nov-2025 19:39:21 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 118.84
$ 123.89
$ 116.74 x 10
$ 122.00 x 4
$ 117.54 - $ 124.00
$ 83.59 - $ 124.61
9,065,913
na
147.44B
$ 0.48
$ 18.18
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-23-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-04-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-22-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-23-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-06-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 02-27-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 02-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

in-oct-gilead-sciences-reached-settlement-with-a-tax-authority-related-to-a-prior-year-legal-entity-restructuring--sees-450m-of-income-tax-benefit-and-a-corresponding-530m-reduction-in-unrecognized-tax-benefits-in-quarter-ending-dec-31
In Oct, Gilead Sciences Reached Settlement...
11/07/2025 21:26:50

-SEC Filing

gileads-trodelvy-misses-main-goal-in-breast-cancer-study-but-shows-early-survival-trend
Gilead's Trodelvy Misses Main Goal In Brea...
11/07/2025 15:10:32

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver ...

gilead-says-phase-3-ascent-07-study-of-trodelvy-did-not-meet-primary-endpoint-of-progression-free-survival
Gilead Says Phase 3 ASCENT-07 Study Of Tro...
11/07/2025 13:31:38

gilead-announces-long-term-data-showing-sustained-efficacy-in-primary-biliary-cholangitis
Gilead Announces Long-Term Data Showing Su...
11/07/2025 13:04:22

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

truist-securities-reiterates-buy-on-gilead-sciences-raises-price-target-to-145
Truist Securities Reiterates Buy on Gilead...
11/03/2025 15:23:56

Truist Securities analyst Asthika Goonewardene reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price targ...

gilead-sciences-and-kite-to-present-21-abstracts-including-5-oral-presentations-showcasing-kites-continued-progress-in-transforming-blood-cancer-care-and-expanding-reach-and-impact-of-car-t-cell-therapy-at-ash-2025
Gilead Sciences And Kite To Present 21 Abs...
11/03/2025 14:21:20

– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented O...

wells-fargo-maintains-overweight-on-gilead-sciences-raises-price-target-to-145
Wells Fargo Maintains Overweight on Gilead...
10/31/2025 21:12:51

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from ...

jp-morgan-maintains-overweight-on-gilead-sciences-raises-price-target-to-150
JP Morgan Maintains Overweight on Gilead S...
10/31/2025 18:36:06

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $1...

gileads-hiv-drugs-power-earnings-beat-company-eyes-multiple-launches-by-2026
Gilead's HIV Drugs Power Earnings Beat, Co...
10/31/2025 17:41:12

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday
Nasdaq 100 Rebounds, Amazon Jumps 10% On S...
10/31/2025 17:26:36

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-105
RBC Capital Maintains Sector Perform on Gi...
10/31/2025 14:57:23

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

cantor-fitzgerald-reiterates-overweight-on-gilead-sciences-maintains-135-price-target
Cantor Fitzgerald Reiterates Overweight on...
10/31/2025 13:36:40

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $135 price t...

needham-reiterates-buy-on-gilead-sciences-maintains-133-price-target
Needham Reiterates Buy on Gilead Sciences,...
10/31/2025 12:13:03

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $133 price target.

gilead-sciences-raises-fy2025-adj-eps-guidance-from-795-825-to-805-825-vs-803-est-raises-fy2025-sales-guidance-from-28300b-28700b-to-28400b-28700b-vs-28842b-est
Gilead Sciences Raises FY2025 Adj EPS Guid...
10/30/2025 20:05:04

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2025 FULL-YEAR GUIDANCE(1)(unaudited)         (in millions, except perc...

gilead-sciences-raises-fy2025-gaap-eps-guidance-from-585-615-to-665-685-vs-598-est
Gilead Sciences Raises FY2025 GAAP EPS Gui...
10/30/2025 20:03:40

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2025 FULL-YEAR GUIDANCE(1)(unaudited)         (in millions, except perc...

gilead-sciences-q3-adj-eps-247-beats-213-estimate-sales-7769b-beat-7446b-estimate
Gilead Sciences Q3 Adj. EPS $2.47 Beats $2...
10/30/2025 20:02:34

Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.47 per share which beat the analyst consensus estimate of $2.13...

meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday
Meta Tumbles 10%, Google Marks Historic Ra...
10/30/2025 17:40:46

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

cvs-health-delivers-confident-outlook-after-q3-performance-stock-hits-52-week-high
CVS Health Delivers Confident Outlook Afte...
10/29/2025 14:20:39

CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segmen...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION